Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200-Day Moving Average – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:POAI)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.47 and traded as low as $6.52. Predictive Oncology shares last traded at $6.7596, with a volume of 40,332 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have recently commented on POAI shares. Wall Street Zen cut shares of Predictive Oncology to a “strong sell” rating in a research note on Saturday, December 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Predictive Oncology in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Predictive Oncology currently has an average rating of “Sell”.

Predictive Oncology Stock Performance

The stock’s fifty day moving average price is $6.22 and its 200-day moving average price is $10.45. The firm has a market cap of $23.16 million, a PE ratio of -0.51 and a beta of 1.35.

Predictive Oncology (NASDAQ:POAI) last issued its earnings results on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($3.17). Predictive Oncology had a negative return on equity of 732.73% and a negative net margin of 5,065.23%.The company had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Sell-side analysts forecast that Predictive Oncology Inc. will post -2.08 earnings per share for the current fiscal year.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.